Pro-life leaders expressed suspicion that the U.S. Food and Drug Administration is intentionally delaying its safety evaluation of mifepristone until after the November 3, 2026, midterm elections

From the articleDA Says It Won't Act On Abortion Drugs Till March, 2 Years After Pledging To Review Safety ConcernsAlso in FDA says it will complete safety review of abortion pill in March